Genotyping Market 2020 Global Market Trends, Share, Size, Growth, Opportunity and Forecast to 2023

The global genotyping market is projected to have a healthy growth at an exponential 22.5% CAGR during the forecast period (2018-2023). Genotyping helps users in understanding a living organism’s genetic structure such as humans, animals, plants and microorganisms. It is basically an organism’s genetic mapping that includes both DNA sequencing as well as sequenced DNA’s analysis. Genotyping has various uses in medicine, agriculture and basic scientific research.

There are several factors that are driving the Genotyping Market Growth. These factors according to the MRFR report include advancements in technology, rising prevalence of target diseases namely Alzheimer’s, diabetes and cancer, introduction of new technologies which reduce errors and offer effective results, increasing R&D activities in healthcare, rise in genetic ailments, surge in need for personalized medication and decrease in genotyping service price. On the contrary, factors such as dearth of skilled professionals and unfavorable reimbursement policies may hamper the growth of the genotyping market.

Key Players

Leading players profiled in the genotyping market include Thermo Fisher Scientific Inc. (USA), Sequenom (USA), Qiagen (Germany), Illumina Inc. (USA), General Electric Company (USA), F. Hoffmann-La Roche Ltd. (Switzerland), Fluidigm Corporation (USA), Beckman Coulter Inc. (USA), Agilent Technologies Inc. (USA), and Affymetrix Inc. (USA).

Feb 2019 - Huasin and Genomica have entered into an agreement through which HuaSin availed exclusive rights for developing and producing HPV genotyping assay platform that is fully automated and uses Genomica’s technology. This genotyping technology will aid in detecting HPV in women prior to the development and spreading of cancer and expects it to also support vaccination programs that are long-needed and evolving.

Market Segmentation

Market Research Future report offers an all-inclusive segmental analysis of the genotyping market on the basis of product, end-user, application and technology.

Based on product, it is segmented into services, reagents and kits and instruments. Of these, reagents and kits will have the largest share in the market.

Based on end-user, the genotyping market is segmented into R&D centers, hospitals, diagnostic centers and academic institutes.

Based on application, it is segmented into personalized medicine, drug discovery and development, agriculture diagnostics and academic research. Of these, personalized medicine will lead the market and is expected to have the fastest growth.

Based on technology, the genotyping market is segmented into polymerase chain reaction (PCR), sequencing, microarray, mass spectrometry and capillary electrophoresis. Capillary electrophoresis is further segmented into single-strand conformation polymorphism (SSCP), restriction fragment length polymorphism (RFLP) and amplified fragment length polymorphism (AFLP). Microarrays is further segmented into peptide microarrays, MMChips, DNA microarrays and antibody microarrays. Sequencing is further segmented into sanger sequencing, pyrosequencing and next-generation sequencing. Of these, sequencing will lead the market during the forecast period.

Browse More Information:- https://www.marketresearchfuture.com/reports/genotyping-market-6635

Regional Analysis

Based on region, the genotyping market covers growth opportunities and latest trends across Americas, Europe, Asia Pacific and Middle East and Africa. Of these, Americas will garner highest share in the market. Owing to technology, North America will have a higher share over South America. The factors that can be attributed for the growth of the market in North America include presence of several key players, accessibility of advanced and innovative medical facilities, rising incidences of genetic disorders, and support from the government for research and development. The USA and Canada are the leading contributors in North America while in South America, Brazil and Argentina will be the key contributors. Europe will have the second largest share in the genotyping market owing to the region’s well-established healthcare sector. The market here is having a favorable growth owing to accessibility of latest and advanced medical facilities, increasing investment in research and development by pharmaceutical companies, presence of leading market players and various governments investing in research and development. Western Europe will have a bigger share than Eastern Europe. The genotyping market in the APAC region is projected to grow at the fastest pace owing to rising disposable income, increasing investment by key market players, stable healthcare sector which is growing gradually and supportive government policies. Here the key contributors are India, Japan, China, Australia and South Korea. On the other hand, the genotyping market in Middle East and Africa will have minimal share owing to most governments not giving priority to healthcare, dearth of healthcare facilities, lack of education, medical facilities having low standard, lack of advanced and innovative medical facilities, lack of awareness and presence of poor countries.